Interaction between the microbiome and TP53 in human lung cancer.
Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, von Muhlinen N, Polley EC, Bowman ED, Khan MA, Robles AI, Cooks T, Ryan BM, Padgett N, Dzutsev AH, Trinchieri G, Pineda MA, Bilke S, Meltzer PS, Hokenstad AN, Stickrod TM, Walther-Antonio MR, Earl JP, Mell JC, Krol JE, Balashov SV, Bhat AS, Ehrlich GD, Valm A, Deming C, Conlan S, Oh J, Segre JA, Harris CC
Genome Biol. 08 2018. doi: 10.1186/s13059-018-1501-6
The authors suggest the interaction between the lung microbiome and the host tissue in lung cancer, particularly in squamous cell carcinoma cases with certain TP53 mutations. By means of 16S analysis, RNA-Seq sequencing and fluorescent in situ hibridization techniques the authors show an enrichment of _Acidovorax_ taxa in lung tissue from squamous cell carcinoma samples. Differences in alpha diversity in the samples taken from normal, tumor-adjacent and tumor tissues were also identified as well as a relation of _Acidovorax_ levels and the presence of TP53 mutations.
As it is remarked in the article, the characterization of the lung microbiome in lung cancer is particularly important in two ways. Firstly, as it might play an important role in the response to immunotherapy (as it has been demonstrated in animal models for the gut microbiome) any advances in the microbiome characterization could be useful to predict the likely therapy effectiveness. Secondly, the microbiome might be used as a biomarker to allow patients stratification.